Grove Biopharma is a biotechnology company offering a materials science solution to peptide therapeutic challenges.
Grove Biopharma has raised $30.0M in total funding. The most recent round was Series A. The last funding was announced in April 2025.
Grove Biopharma's investors include Eli Lilly, DCVC Bio, DeepWork Capital, Portal Innovations, Viva BioInnovator.
Grove Biopharma is headquartered in Chicago, United States.
Grove Biopharma is a biotechnology company offering a materials science solution to peptide therapeutic challenges.
Grove Biopharma is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Grove Biopharma — Funding & Investors." VCBacked, April 23, 2025, https://www.vcbacked.co/company/grove-biopharma. Accessed October 26, 2026.
VCBacked. (2025). Grove Biopharma — Funding & Investors. Retrieved October 26, 2026, from https://www.vcbacked.co/company/grove-biopharma
{{cite web |title=Grove Biopharma — Funding & Investors |url=https://www.vcbacked.co/company/grove-biopharma |website=VCBacked |access-date=October 26, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated